Company intelligence / Profile preview

Lindis Biotech GmbH

Planegg/Martinsried, Bavaria, Germanylindisbiotech.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Lindis Biotech develops innovative immuno-oncology therapies based on its proprietary Triomab® platform. Its lead product catumaxomab was the first T-cell engaging multi-specific antibody approved worldwide. The company has three advanced clinical candidates targeting high unmet needs such as malignant ascites and non-muscle invasive bladder cancer. Recent licensing agreements aim to commercialize these assets further.

Therapeutic areas: Oncology
Modalities: Trifunctional bispecific antibodies (Triomab® platform)Monoclonal antibodies
Industry: Biotech

Drug pipeline

3 assets

catumaxomab

2 more assets in the full pipeline.

Partnerships

Pharmanovia – exclusive licensee/commercialization partner for catumaxomab in EuropeCelonic Group – manufacturing partner for commercial supply of catumaxomab

Beyond the preview

Go deeper on Lindis Biotech GmbH.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lindis Biotech GmbH.